抗瓜氨酸化蛋白抗体特异性、类风湿因子同种型与新发心血管事件的关系
研究纳入2814例瑞典新发类风湿关节炎患者,中位随访13年,发现抗CCP2抗体及ACPA特异性数量与急性冠脉综合征、卒中、心血管死亡和MACE相关;IgM-RF与除ACS外的心血管终点相关,IgA-RF仅与心血管死亡相关,且校正后仍显著。
要点
- 抗CCP2阳性与ACS、卒中、心血管死亡和MACE风险增加相关。
- ACPA特异性数量与心血管事件相关,但无法归因于特定特异性。
- IgA-RF与心血管死亡独立相关,校正混杂因素后仍显著。
核心结论
- RF同种型和ACPA与RA患者未来心血管事件相关。
- ACPA水平和特异性数量似乎比特定特异性更重要,且关联不能由吸烟史解释。
研究设计与样本
- 瑞典新发RA患者(1996-2009年诊断,症状出现1年内)血清中心检测抗CCP2、20种ACPA特异性和RF同种型。
- 通过全国登记纵向随访,使用Cox比例风险模型评估血清学标志与心血管结局的关联。
主要发现
- 共纳入2814例RA患者,中位随访13年,375例发生ACS、卒中或心血管死亡。
- 抗CCP2与ACS(HR 1.46,95%CI 1.03-2.06)、卒中(HR 1.47,95%CI 1.03-2.10)、心血管死亡(P=0.024)和MACE(HR 1.34,95%CI 1.06-1.70)相关。
- IgM-RF与除ACS外所有心血管终点相关,IgA-RF仅与心血管死亡相关(校正后HR 1.61,95%CI 1.05-2.48)。
- 所有评估的血清学标志均与全因死亡率相关。
关键数值与推荐
- 抗CCP2与ACS的HR为1.46(95%CI 1.03-2.06),与卒中的HR为1.47(95%CI 1.03-2.10)。
- 抗CCP2水平与心血管死亡关联的P=0.024。
- 抗CCP2与MACE的HR为1.34(95%CI 1.06-1.70)。
- IgA-RF与心血管死亡的校正后HR为1.61(95%CI 1.05-2.48)。
临床怎么用
- 对RA患者检测抗CCP2和RF同种型可能有助于识别心血管事件高风险者。
- ACPA水平和特异性数量可作为心血管风险分层的参考,而非仅关注特定特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the relationship between anti-citrullinated protein antibodies (ACPAs), specific ACPA subspecificities, rheumatoid factor (RF) isotypes, and incident cardiovascular (CV) events in patients with rheumatoid arthritis (RA). METHODS: Serum samples from Swedish patients with new-onset RA (diagnosed within 1 year of symptom onset between 1996 and 2009) were centrally typed for anti-cyclic citrullinated peptide 2 (anti-CCP2) antibodies, 20 ACPA subspecificities, and RF isotypes. Patients were followed up longitudinally in nationwide registers to monitor the occurrence of acute coronary syndrome (ACS), stroke, CV-related death, and major adverse CV events (MACE). The association between each serologic marker and CV outcome, and the impact of adjustment for the Disease Activity Score in 28 joints (DAS28), smoking status, and income at baseline, were assessed using Cox proportional hazards models. In addition, associations of serologic markers with all-cause mortality were explored. RESULTS: In total, 2,814 patients with RA were included in the study. The median follow-up was 13 years, during which the CV end points of ACS, stroke, or CV-related death were reported to occur in 375 patients. Occurrence and/or levels of anti-CCP2 were associated with risk of incident ACS (hazard ratio [HR] 1.46, 95% confidence interval [95% CI] 1.03-2.06), stroke (HR 1.47, 95% CI 1.03-2.10), CV-related death (P = 0.024 for association with anti-CCP2 levels), and MACE (HR 1.34, 95% CI 1.06-1.70). Similarly, an association with the number of ACPA subspecificities was observed; however, this could not be attributed to any individual or group of ACPA subspecificities. Presence of IgM-RF was associated with all CV end points except ACS, and IgA-RF was exclusively associated with CV-related death. Adjustment for smoking status, income, and DAS28 scores decreased most of the HRs, whereas IgA-RF remained associated with CV-related death (HR 1.61, 95% CI 1.05-2.48). All of the assessed serologic makers were associated with all-cause mortality. CONCLUSION: RF isotypes and ACPAs are associated with future CV events in patients with RA. ACPA levels and number of subspecificities seem more important than the occurrence of particular subspecificities, and these associations were not explained by a history of ever smoking.
引用
- Westerlind H, Rönnelid J, Hansson M, et al. Anti-Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 32475073. doi:10.1002/art.41381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。